205 related articles for article (PubMed ID: 26597462)
1. Sexual activity and functioning after risk-reducing salpingo-oophorectomy: Impact of hormone replacement therapy.
Johansen N; Liavaag AH; Tanbo TG; Dahl AA; Pripp AH; Michelsen TM
Gynecol Oncol; 2016 Jan; 140(1):101-6. PubMed ID: 26597462
[TBL] [Abstract][Full Text] [Related]
2. Hormone replacement therapy after risk-reducing salpingo-oophorectomy minimises endocrine and sexual problems: A prospective study.
Vermeulen RFM; Beurden MV; Kieffer JM; Bleiker EMA; Valdimarsdottir HB; Massuger LFAG; Mourits MJE; Gaarenstroom KN; van Dorst EBL; van der Putten HWHM; Aaronson NK
Eur J Cancer; 2017 Oct; 84():159-167. PubMed ID: 28818705
[TBL] [Abstract][Full Text] [Related]
3. Sexual functioning more than 15 years after premenopausal risk-reducing salpingo-oophorectomy.
Terra L; Beekman MJ; Engelhardt EG; Heemskerk-Gerritsen BAM; van Beurden M; Roeters van Lennep JE; van Doorn HC; de Hullu JA; Van Dorst EBL; Mom CH; Slangen BFM; Gaarenstroom KN; van der Kolk LE; Collée JM; Wevers MR; Ausems MGEM; Van Engelen K; van de Beek I; Berger LPV; van Asperen CJ; Gomez Garcia EB; Maas AHEM; Hooning MJ; Aaronson NK; Mourits MJE; van Leeuwen FE
Am J Obstet Gynecol; 2023 Apr; 228(4):440.e1-440.e20. PubMed ID: 36403862
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of sexual dysfunction after risk-reducing salpingo-oophorectomy.
Tucker PE; Bulsara MK; Salfinger SG; Tan JJ; Green H; Cohen PA
Gynecol Oncol; 2016 Jan; 140(1):95-100. PubMed ID: 26545955
[TBL] [Abstract][Full Text] [Related]
5. Use of hormone replacement therapy after risk-reducing salpingo-oophorectomy.
Johansen N; Liavaag AH; Iversen OE; Dørum A; Braaten T; Michelsen TM
Acta Obstet Gynecol Scand; 2017 May; 96(5):547-555. PubMed ID: 28236297
[TBL] [Abstract][Full Text] [Related]
6. Hormone Levels and Sexual Functioning After Risk-Reducing Salpingo-Oophorectomy.
Johansen N; Liavaag AH; Mørkrid L; Michelsen TM
Sex Med; 2018 Jun; 6(2):143-153. PubMed ID: 29631858
[TBL] [Abstract][Full Text] [Related]
7. Osteoporosis risk and management in BRCA1 and BRCA2 carriers who undergo risk-reducing salpingo-oophorectomy.
Garcia C; Lyon L; Conell C; Littell RD; Powell CB
Gynecol Oncol; 2015 Sep; 138(3):723-6. PubMed ID: 26086567
[TBL] [Abstract][Full Text] [Related]
8. Satisfaction with prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers is very high and little dependent on the participants' characteristics at surgery: a prospective study.
Grandi G; Sammarini M; Cortesi L; Toss A; Botticelli L; Varliero F; Sighinolfi G; Barbieri E; Facchinetti F
Menopause; 2021 Feb; 28(3):263-270. PubMed ID: 33534430
[TBL] [Abstract][Full Text] [Related]
9. Attitudes towards risk-reducing early salpingectomy with delayed oophorectomy for ovarian cancer prevention: a cohort study.
Gaba F; Blyuss O; Chandrasekaran D; Osman M; Goyal S; Gan C; Izatt L; Tripathi V; Esteban I; McNicol L; Ragupathy K; Crawford R; Evans DG; Legood R; Menon U; Manchanda R
BJOG; 2021 Mar; 128(4):714-726. PubMed ID: 32803845
[TBL] [Abstract][Full Text] [Related]
10. Sexual function, menopausal symptoms, depression and cancer worry in women with BRCA mutations.
Powell CB; Alabaster A; Le A; Stoller N; Armstrong MA; Raine-Bennett T
Psychooncology; 2020 Feb; 29(2):331-338. PubMed ID: 31654466
[TBL] [Abstract][Full Text] [Related]
11. Bone mineral density and fractures after risk-reducing salpingo-oophorectomy in women at increased risk for breast and ovarian cancer.
Fakkert IE; Abma EM; Westrik IG; Lefrandt JD; Wolffenbuttel BH; Oosterwijk JC; Slart RH; van der Veer E; de Bock GH; Mourits MJ
Eur J Cancer; 2015 Feb; 51(3):400-8. PubMed ID: 25532426
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcomes of risk-reducing surgery in unaffected women at increased familial risk of breast and/or ovarian cancer.
Heiniger L; Butow PN; Coll J; Bullen T; Wilson J; Baylock B; Meiser B; Price MA
Fam Cancer; 2015 Mar; 14(1):105-15. PubMed ID: 25283514
[TBL] [Abstract][Full Text] [Related]
13. Sexuality and quality of life in women with a prior diagnosis of breast cancer after risk-reducing salpingo-oophorectomy.
Tucker PE; Saunders C; Bulsara MK; Tan JJ; Salfinger SG; Green H; Cohen PA
Breast; 2016 Dec; 30():26-31. PubMed ID: 27592287
[TBL] [Abstract][Full Text] [Related]
14. The effects of pre-operative menopausal status and hormone replacement therapy (HRT) on sexuality and quality of life after risk-reducing salpingo-oophorectomy.
Tucker PE; Bulsara MK; Salfinger SG; Tan JJ; Green H; Cohen PA
Maturitas; 2016 Mar; 85():42-8. PubMed ID: 26857878
[TBL] [Abstract][Full Text] [Related]
15. Fatigue and quality of life after risk-reducing salpingo-oophorectomy in women at increased risk for hereditary breast-ovarian cancer.
Michelsen TM; Dørum A; Tropé CG; Fosså SD; Dahl AA
Int J Gynecol Cancer; 2009 Aug; 19(6):1029-36. PubMed ID: 19820364
[TBL] [Abstract][Full Text] [Related]
16. The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy.
Madalinska JB; van Beurden M; Bleiker EM; Valdimarsdottir HB; Hollenstein J; Massuger LF; Gaarenstroom KN; Mourits MJ; Verheijen RH; van Dorst EB; van der Putten H; van der Velden K; Boonstra H; Aaronson NK
J Clin Oncol; 2006 Aug; 24(22):3576-82. PubMed ID: 16877724
[TBL] [Abstract][Full Text] [Related]
17. A controlled study of mental distress and somatic complaints after risk-reducing salpingo-oophorectomy in women at risk for hereditary breast ovarian cancer.
Michelsen TM; Dørum A; Dahl AA
Gynecol Oncol; 2009 Apr; 113(1):128-33. PubMed ID: 19178933
[TBL] [Abstract][Full Text] [Related]
18. Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in BRCA1/2 Pathogenic Variant Carriers: A Nonrandomized Controlled Trial.
Steenbeek MP; Harmsen MG; Hoogerbrugge N; de Jong MA; Maas AHEM; Prins JB; Bulten J; Teerenstra S; van Bommel MHD; van Doorn HC; Mourits MJE; van Beurden M; Zweemer RP; Gaarenstroom KN; Slangen BFM; Brood-van Zanten MMA; Vos MC; Piek JMJ; van Lonkhuijzen LRCW; Apperloo MJA; Coppus SFPJ; Massuger LFAG; IntHout J; Hermens RPMG; de Hullu JA
JAMA Oncol; 2021 Aug; 7(8):1203-1212. PubMed ID: 34081085
[TBL] [Abstract][Full Text] [Related]
19. Systematic review of acceptability, cardiovascular, neurological, bone health and HRT outcomes following risk reducing surgery in BRCA carriers.
Gaba F; Manchanda R
Best Pract Res Clin Obstet Gynaecol; 2020 May; 65():46-65. PubMed ID: 32192936
[TBL] [Abstract][Full Text] [Related]
20. Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing risk-reducing salpingo-oophorectomy.
Gabriel CA; Tigges-Cardwell J; Stopfer J; Erlichman J; Nathanson K; Domchek SM
Fam Cancer; 2009; 8(1):23-8. PubMed ID: 18758995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]